News

Merck buys Raleigh pharma company for $10 billion, drawn by new COPD drug
Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Merck: FDA to Review Doravirine/Islatravir Regimen in HIV-1 Infection
Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...
Merck & Co.: A Pharma Titan At A Discount
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Fierce Pharma3h
Pressuring Merck's Gardasil, China's home-made 9-valent HPV vaccine priced at 60% discount
China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 ...
Barchart on MSN1d
What You Need To Know Ahead of Merck's Earnings Release
Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...
Merck shells out $10 billion for London-based lung therapy firm Verona
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...